121174 20240319081015.0 doi 10.3390/jcm11133915 sideral 131826 ART-2022-131826 eng Riestra, Sabino Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU 2022 Access copy available to the general public Unrestricted (1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-ץ-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18–20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50–0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66–0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20–22%] vs. 14% [95% CI 13–16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM. info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 3.9 2022 MEDICINE, GENERAL & INTERNAL 58 / 169 = 0.343 2022 Q2 T2 0.935 2022 Medicine (miscellaneous) 2022 Q1 5.4 2022 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Taxonera, Carlos Zabana, Yamile Carpio, Daniel Chaparro, María Barrio, Jesús Rivero, Montserrat López-Sanroman, Antonio Esteve, María de Francisco, Ruth Bastida, Guillermo García-López, Santiago Universidad de Zaragoza (orcid)0000-0003-3970-5457 Mañosa, Miriam Martin-Arranz, María Dolores Pérez-Calle, José Lázaro Guardiola, Jordi Muñoz, Fernando Arranz, Laura Cabriada, José Luis García-Sepulcre, Mariana Fe Navarro, Mercè Montoro-Huguet, Miguel Ángel Ricart, Elena Bermejo, Fernando Calvet, Xavier Piqueras, Marta Garcia-Planella, Esther Márquez, Lucía Mínguez, Miguel Van Domselar, Manuel Bujanda, Luis Aldeguer, Xavier Sicilia, Beatriz Iglesias, Eva Alcaín, Guillermo Pérez-Martínez, Isabel Rolle, Valeria Castaño-García, Andrés P. Gisbert, Javier Domènech, Eugeni 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 11, 13 (2022), 3915 [12 pp.] J. clin.med. Journal of Clinical Medicine 2077-0383 458273 http://zaguan.unizar.es/record/121174/files/texto_completo.pdf Versión publicada 3111471 http://zaguan.unizar.es/record/121174/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:121174 articulos driver 2024-03-18-15:34:55 ARTICLE